Navin Fluorine International Ltd

- There is no explicit mention in the transcript of any current or future fundraising plans through debt or equity. - The company indicates a disciplined approach to growth with a net debt-to-equity ratio of 0.03x as of December 31, FY25, reflecting low leverage. - Ongoing CAPEX projects are progressing well, but financing details or plans for raising funds via new debt or equity are not disclosed. - The focus seems to be on executing existing CAPEX and driving growth through operations and partnerships without indicating new fundraising. - No announcements or indications of equity issuance or debt raising are made in the provided pages.

- Completed Wave-1 CAPEX projects, including cGMP-4 Phase-1 facility and AHF project, both commissioned and commercial supplies started. - Ongoing Wave-2 CAPEX projects on track: MPP debottlenecking, R-32 expansion, HFC expansion, and Chemours project. - Nectar plant added; aiming to utilize full capacity by FY27. - CDMO dedicated plant expected to be fully utilized in FY27. - Focus on advanced materials and downstream fluorinated chemistries for new age industries, including semiconductors and data centers globally and in India. - Emphasis on capacity expansion balanced with disciplined project execution. - Future CAPEX will target electronic-grade AHF production and downstream applications to leverage semiconductor and solar opportunities. - Chemours project expected to ramp up over FY27-FY29 with potential for additional larger CAPEX. - Strategy includes increasing captive consumption of AHF to support niche chemistries and advanced materials growth.

- Strong growth momentum expected across all three business verticals: Specialty Chemicals, CDMO, and HPP, supported by ongoing capacity expansions and positive pricing trends (Pages 4, 6, 12). - Specialty Chemicals division achieved its highest-ever quarterly revenue; further growth expected with ramp-up of Nectar project and other pipeline products (Pages 6, 12, 18). - CDMO is witnessing significant deal wins and balanced portfolio of early and late-stage molecules; aiming to fully utilize dedicated cGMP-4 plant capacity in FY27 and inch closer to $100 million revenue aspirational mark (Pages 18, 12). - Agrochemical volume outlook looks positive in FY27 after two rough years, with good capacity utilization and pipeline of new molecules supporting volume growth (Page 16). - Exports to EU and other geographies expected to rise as business expands into newer markets aided by trade agreements and competitive positioning (Page 17). - Overall revenue growth: 47% YoY in Q3 FY26, with full year FY25 revenues surpassed in first nine months of FY26, indicating strong forward trajectory (Page 6).

- Navin Fluorine expects continued strong growth across all verticals driven by ongoing CAPEX projects and expanding capacities. - Specialty Chemicals division has set a new high in quarterly revenue, indicating a solid growth run rate. - CDMO business is ramping up, aiming for the aspirational $100 million revenue mark in the near future. - The cGMP-4 phase-I plant is expected to reach full utilization within FY27, supporting revenue growth. - EBITDA margins are expected to stabilize around 30% on an annualized basis, with operating leverage playing a significant role in earnings growth. - The company anticipates balanced growth from early and late-stage molecules in CDMO, potentially accelerating revenue conversion. - Earnings growth rate surpasses revenue growth due to strong operating leverage and margin improvements. - Staff costs are expected to remain controlled at 7-8% of revenue, helping margin sustainability. - Net debt-to-equity remains low at 0.03x, supporting disciplined growth financials.

- Navin Fluorine International Limited has a strong pipeline of projects and order visibility across all verticals. - The CDMO (Contract Development and Manufacturing Organization) business continues to build momentum with strong order visibility. - The Specialty Chemicals division has achieved its highest-ever quarterly revenue, reflecting strong execution and deeper partnerships. - Wave-1 CAPEX projects like AHF and cGMP-4 Phase-1 have been commissioned and are operational. - Wave-2 projects including MPP debottlenecking, R-32 expansion, HFC expansion, and the Chemours project are on track for completion. - The company is actively working on expanding capabilities and aiming for optimal utilization of new plants within FY27. - Growth opportunities are backed by policy support like the Semiconductor Mission 2.0 and trade agreements enhancing order inflows. - Overall, clear order visibility and a strong project pipeline support confidence in the company’s growth trajectory.